| XLS |
|
|
|
|
|
|
|
€ million |
Q2 – 2013 |
Q2 – 2012 |
Jan.–June 2013 |
Jan.–June 2012 |
|
Sales |
2,743.9 |
2,743.1 |
5,404.3 |
5,307.0 |
|
Royalty, license and commission income |
97.2 |
109.0 |
197.3 |
190.1 |
|
Total revenues |
2,841.1 |
2,852.1 |
5,601.6 |
5,497.1 |
|
|
|
|
|
|
|
Cost of sales |
–768.0 |
–807.8 |
–1,492.0 |
–1,556.5 |
|
Gross profit |
2,073.1 |
2,044.3 |
4,109.6 |
3,940.5 |
|
|
|
|
|
|
|
Marketing and selling expenses |
–616.3 |
–617.3 |
–1,184.6 |
–1,203.8 |
|
Royalty, license and commission expenses |
–156.5 |
–151.7 |
–292.8 |
–271.7 |
|
Administration expenses |
–137.5 |
–142.6 |
–270.2 |
–279.0 |
|
Other operating expenses and income |
–115.9 |
–488.7 |
–299.9 |
–633.2 |
|
Research and development |
–373.5 |
–404.0 |
–779.7 |
–785.8 |
|
Amortization of intangible assets |
–209.4 |
–217.4 |
–419.0 |
–433.7 |
|
Investment result |
1.4 |
0.5 |
1.4 |
0.5 |
|
Operating result (EBIT) |
465.4 |
23.2 |
864.8 |
333.8 |
|
|
|
|
|
|
|
Financial result |
–48.5 |
–69.7 |
–107.2 |
–135.8 |
|
Profit before income tax |
416.9 |
–46.5 |
757.6 |
198.0 |
|
|
|
|
|
|
|
Income tax |
–100.8 |
–14.1 |
–172.5 |
–83.4 |
|
Profit after tax |
316.1 |
–60.5 |
585.1 |
114.6 |
|
|
|
|
|
|
|
of which attributable to Merck KGaA shareholders (net income) |
316.0 |
–63.2 |
582.0 |
109.5 |
|
of which non-controlling interest |
0.1 |
2.7 |
3.1 |
5.1 |
|
|
|
|
|
|
|
Earnings per share (in €) |
|
|
|
|
|
basic |
1.45 |
–0.29 |
2.68 |
0.50 |
|
diluted |
1.45 |
–0.29 |
2.68 |
0.50 |